Otsuka Holdings Co (OS1) Q2 2024 Earnings Report

The earnings call highlighted strong growth in revenue and business profit, driven by pharmaceutical and nutraceutical segments. Forecasts have been revised upward, and there is an acquisition to further enhance drug discovery capabilities. However, there were some negatives, such as impairment losses and a decrease in certain revenues. Overall, the positive aspects significantly outweigh the negatives, indicating a strong performance and optimistic outlook.

During the Q2 2024 earnings call for 4578.T, the executives provided detailed guidance reflecting significant growth in both their pharmaceutical and nutraceutical segments. Revenue increased by 17.0% year-on-year to JPY 1,108.9 billion, while business profit surged by 37.8% to JPY 213.6 billion, driven primarily by strong sales of Core 2 pharmaceutical products like ABILIFY MAINTENA and JYNARQUE, and nutraceuticals, particularly in the For Women’s Health category. Despite an impairment loss on AVP-786, net profit rose by 5.1% due to finance income. The company also revised its full-year forecast upwards, with revenue now expected to reach JPY 2,315 billion and business profit JPY 390 billion. Nutraceutical revenue saw a notable increase, achieving over a 20% growth rate to JPY 271.8 billion, fueled by the expansion of products like Bonafide and Nature Made. Additionally, the company announced plans for share repurchases amounting to JPY 50 billion as part of their shareholder return policy.